sorafenib has been researched along with phosphoserine in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (phosphoserine) | Trials (phosphoserine) | Recent Studies (post-2010) (phosphoserine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 3,337 | 3 | 830 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YH; Chen, CT; Chow, LP; Huang, BS; Li, NC; Liao, LZ; Lin, LC | 1 |
1 other study(ies) available for sorafenib and phosphoserine
| Article | Year |
|---|---|
Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Neoplasm Invasiveness; Phosphorylation; Phosphoserine; Prognosis; Pseudopodia; Reproducibility of Results; Signal Transduction; Sorafenib; Spheroids, Cellular; Y-Box-Binding Protein 1 | 2020 |